acquir
morn alexion enter agreement acquir outstand portola share
per share cash total deal unanim approv alexion
portola board director
portola could seen strateg fit larg biotech/pharma compani though
think interest bid higher price point might limit bristol
licens develop commerci andexanet alfa japan
agreement recent termin transact come robust premium
roughli in-lin estim ptla npv scenario see overlap
pipeline/commerci product would expect major anti-trust concern
deal
transact diversifi alexion commerci product may reduc
relianc complement franchis time leverag exist global
commerci infrastructur relationship hospit channel
rais tp increas tp match offer price
shift npv weight adjust expect revenu estim
risk neutral rate target price higher competit bid
delay/termin transact
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
portola biopharmaceut compani focus develop
commerci novel therapeut area thrombosi
hematolog disord inflamm patient current
limit approv treatment option
blue sky valuat base potenti higher bid
competitor
grey sky valuat base alexion acquisit go
dcf analysi driven combin sale andexxa
peak
 close
compani mention price
tiago fauth certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
